January 10, 2012
A New Jersey federal judge on Tuesday preliminarily approved a settlement in a shareholder derivative suit accusing former Schering-Plough Corp. directors of hiding the lackluster performance of the Merck & Co. Inc. unit's anti-cholesterol drug Vytorin for nearly two years after a clinical trial.